Effect of Staphylococcus Aureus on the NLRP3 Inflammasome, Caspase-1 and IL-1 β Expression in the Nasal Epithelial Cells in Chronic Rhinosinusitis

Year 2019, Volume: 2 Issue: 1, 6 - 12, 29.05.2019

Amanj Saber Rashida Hussain Sravya Nakka Svante Hugosson

Abstract

Objective: This study aimed to elucidate the effect of Staphylococcus aureus and budesonide on the mRNA expression and the biologic role (caspase-1 activation and IL-1β secretion) of NLRP3 inflammasome in primary nasal epithelial cells (NECs) in patients with chronic rhinosinusitis (CRS) and healthy controls.

Material and Methods: Brush biopsies isolated from both patients and healthy controls were denoted respectively for our experiments. These were treated with S. aureus strains (four strains) only and in combination with budesonide (0, 10, 100, 1000 nM). NECs treated with only budesonide (0, 10, 100, 1000 nM) and untreated NECs were used as controls. Expression of NLRP3, caspase-1, IL-1β along with NLRC1/2 was analyzed by qPCR. Caspase-1 activity was measured by fluorogenic substrates Ac-YVAD-AMC. Enzyme-linked immunosorbent (ELISA) assay was performed to
measure IL-1β production.

Results: The mRNA levels of NLRC1, NLRC2, caspase-1, and IL-1β significantly increased, while NLRP3 demonstrated a trend toward elevation in the CRS group compared to the healthy controls. Infection with S. aureus increased caspase-1 activity and IL-1β secretion. However, treatment with budesonide decreased mRNA expression of NLRC2 and IL-1β secretion.

Conclusion: Increase in the caspase-1 activity and IL-1β levels, due to possible activation of NLRP3 inflammasomes, upon S. aureus infection, may have an important role in the pathogenesis of CRS.

Keywords

Budesonide , chronic rhinosinusitis , NLRP3 , S. aureus

References

• Bachert C, Holtappels G. Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options. GMS Curr Top Otorhinolaryngol Head Neck Surg 2015; 14: Doc09.
• Thunberg U, Soderquist B, Hugosson S. Bacterial findings in optimised sampling and characterisation of S. aureus in chronic rhinosinusitis. Eur Arch Otorhinolaryngol 2017; 274: 311-9.
• Foreman A, Wormald PJ. Different biofilms, different disease? A clinical outcomes study. Laryngoscope 2010; 120: 1701-6.
• Clement S, Vaudaux P, Francois P, Schrenzel J, Huggler E, Kampf S, et al. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J Infect Dis 2005; 192: 1023-8.
• Lane AP, Truong-Tran QA, Myers A, Bickel C, Schleimer RP. Serum amyloid A, properdin, complement 3, and toll-like receptors are expressed locally in human sinonasal tissue. Am J Rhinol 2006; 20: 117-23.
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-26.
• Abderrazak A, Syrovets T, Couchie D, El Hadri K, Friguet B, Simmet T, et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol 2015; 4: 296-307.
• Lin H, Li Z, Lin D, Zheng C, Zhang W. Role of NLRP3 Inflammasome in Eosinophilic and Non-eosinophilic Chronic Rhinosinusitis with Nasal Polyps. Inflammation 2016; 39: 2045-52.
• Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-32.
• Wang H, Lv C, Wang S, Ying H, Weng Y, Yu W. NLRP3 Inflammasome Involves in the Acute Exacerbation of Patients with Chronic Obstructive Pulmonary Disease. Inflammation 2018; 41: 1321-33.
• Pinkerton JW, Kim RY, Robertson AAB, Hirota JA, Wood LG, Knight DA, et al. Inflammasomes in the lung. Mol Immunol 2017; 86: 44-55.
• McAlindon ME, Hawkey CJ, Mahida YR. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 1998; 42: 214-9.
• Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev 2011; 22: 189-95.
• Lennard CM, Mann EA, Sun LL, Chang AS, Bolger WE. Interleukin-1 beta, interleukin-5, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in chronic sinusitis: response to systemic corticosteroids. Am J Rhinol 2000; 14: 367-73.
• Otto BA, Wenzel SE. The role of cytokines in chronic rhinosinusitis with nasal polyps. Curr Opin Otolaryngol Head Neck Surg 2008; 16: 270-4.
• Bogefors J, Rydberg C, Uddman R, Fransson M, Månsson A, Benson M, et al. Nod1, Nod2 and Nalp3 receptors, new potential targets in treatment of allergic rhinitis? Allergy 2010; 65: 1222-6.
• Schleimer RP. Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorac Soc 2004; 1: 222-30.
• Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012; 23: 1-298.
• Hussain R, Hugosson S, Roomans GM. Isolation and culture of primary human nasal epithelial cells from anesthetized nasal epithelia. Acta Otolaryngol 2014; 134: 296-9.
• Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008; 3: 1125-31.
• Bachert C, Zhang N. Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'. J Intern Med 2012; 272: 133-43.
• Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-26.
• Mansson A, Bogefors J, Cervin A, Uddman R, Cardell LO. NOD-like receptors in the human upper airways: a potential role in nasal polyposis. Allergy 2011; 66: 621-8.
• Correa RG, Milutinovic S, Reed JC. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci Rep 2012; 32: 597-608.
• Sejima T, Holtappels G, Kikuchi H, Imayoshi S, Ichimura K, Bachert C. Cytokine profiles in Japanese patients with chronic rhinosinusitis. Allergol Int 2012; 61: 115-22.
• Hosseinian N, Cho Y, Lockey RF, Kolliputi N. The role of the NLRP3 inflammasome in pulmonary diseases. Ther Adv Respir Dis 2015; 9: 188-97.
• Eloy P, Poirrier AL, De Dorlodot C, Van Zele T, Watelet JB, Bertrand B. Actual concepts in rhinosinusitis: a review of clinical presentations, inflammatory pathways, cytokine profiles, remodeling, and management. Curr Allergy Asthma Rep 2011; 11: 146-62.
• Riechelmann H, Deutschle T, Rozsasi A, Keck T, Polzehl D, Bürner H. Nasal biomarker profiles in acute and chronic rhinosinusitis. Clin Exp Allergy 2005; 35: 1186-91.
• van Drunen CM, Mjosberg JM, Segboer CL, Cornet ME, Fokkens WJ. Role of innate immunity in the pathogenesis of chronic rhinosinusitis: progress and new avenues. Curr Allergy Asthma Rep 2012; 12: 120-6.
• von Scheele I, Larsson K, Palmberg L. Budesonide enhances Toll-like receptor 2 expression in activated bronchial epithelial cells. Inhal Toxicol 2010; 22: 493-9.